Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
IBB vs IJS: how they differ
IBB and IJS hold 0% of their weight in the same names, and IBB returned more over the year.
iShares Biotechnology ETF and iShares S&P Small-Cap 600 Value ETF.
What they hold in common
By the books each fund has filed, IBB and IJS hold 0% of their money in the same securities at the same weight.
| Holding | IBB | IJS |
|---|---|---|
| Fortrea Holdings, Inc. | 0.13% | 0.18% |
| Arcus Biosciences, Inc. | 0.20% | 0.11% |
| Xencor, Inc. | 0.09% | 0.13% |
| Sarepta Therapeutics, Inc. | 0.14% | 0.08% |
| Vir Biotechnology, Inc. | 0.11% | 0.08% |
| Only in IBB | Only in IJS |
|---|---|
| Vertex Pharmaceuticals, Inc. 8.09% | MOLINA HEALTHCARE INC 1.30% |
| Amgen, Inc. 7.84% | MATCH GROUP INC 0.97% |
| Gilead Sciences, Inc. 6.85% | EASTMAN CHEMICAL COMPANY 0.84% |
| Regeneron Pharmaceuticals, Inc. 4.91% | CARMAX INC 0.82% |
| Argenx SE 3.76% | KULICKE AND SOFFA INDUSTRIES INC 0.77% |
| Alnylam Pharmaceuticals, Inc. 3.12% | POOL CORP 0.75% |
| Natera, Inc. 2.89% | LKQ CORP 0.73% |
| Revolution Medicines, Inc. 2.78% | VISHAY INTERTECHNOLOGY INC 0.73% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026.
| IBB iShares Biotechnology ETF | IJS iShares S&P Small-Cap 600 Value ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | iShares | iShares |
| What it is | Biotechnology | S&P Small-Cap 600 Value |
| Total return, 1 year | +41.5% | +22.1% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | +24.0 pts | +4.7 pts |
| Expense ratio | 0.44% | 0.18% |
| Already in the S&P 500 | 35.6% | 0.0% |
| Holdings | 248 | 461 |
IBB in plain words
IBB is an index equity fund tracking the Biotechnology. Over the year to Sep 11, 2026 it returned +41.5% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.44% a year. By its holdings filed for Jun 30, 2026, 36% of the fund by weight is stocks the S&P 500 also holds, across 248 positions, with the top ten at 44.8%. It sat 6.5% below its high of Aug 19, 2026 on Sep 11, 2026.
IJS in plain words
IJS is an index equity fund tracking the S&P Small-Cap 600 Value. Over the year to Sep 11, 2026 it returned +22.1% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.18% a year. By its holdings filed for Jun 30, 2026, 0% of the fund by weight is stocks the S&P 500 also holds, across 461 positions, with the top ten at 8.3%. It sat 4.3% below its high of Aug 14, 2026 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, IBB or IJS?
- In the year to Sep 12, 2026, with distributions reinvested, IBB returned +41.5% and IJS returned +22.1%, so IBB returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, IBB or IJS?
- IBB charges 0.44% a year and IJS charges 0.18%, so IJS is cheaper. Fees come from each fund's prospectus.
- How much do IBB and IJS overlap with the S&P 500?
- By their latest filed holdings, 36% of IBB and 0% of IJS by weight is stocks the S&P 500 already holds. Between the two funds, 0% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, IBB against IJS, data as of Sep 12, 2026. https://etfiq.com/compare/any/IBB-IJS Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources